Biotech | March 14, 2022
Clarivate deals report highlights emerging trends in biopharma deal-making
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
In numerous neurological and rare disorders, where clinical characteristics can be confusing, NGS-based approaches have demonstrated considerable increases in disease detection rates over other approaches
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Its technology-centric solutions enable hospitals to enhance operational efficiency and enable faster clinical decision making
Govt announces vaccination programme for kids and those above 60 years of age
The award recognizes and supports promising women scientists
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
Most recently, Rollins was the Chief Information Officer at UnitedHealthcare
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
Subscribe To Our Newsletter & Stay Updated
